{
    "clinical_study": {
        "@rank": "161356", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive GSK Biologicals' adjuvanted investigational vaccine and a placebo (Step 1)."
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects in this group will receive Engerix-B and a placebo (Step 1)."
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in this group will receive GSK Biologicals' adjuvanted investigational vaccine (Step 2)."
            }, 
            {
                "arm_group_label": "Group D", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects in this group will receive Engerix-B (Step 2)."
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to develop innovative immunological read-outs and new technologies in order\n      to further characterise the early immune response and its kinetics as well as the adaptive\n      immune responses to adjuvanted vaccines.\n\n      This study will also evaluate the reactogenicity in healthy, hepatitis B virus naive adults\n      vaccinated with the hepatitis B surface antigen in combination with a GSK Biologicals'\n      Adjuvant System."
        }, 
        "brief_title": "Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will be conducted in 2 steps:\n\n        -  Step 1 will aim at the development of innate and adaptive read-outs. This evaluation of\n           the early immune response will lead to the selection of the most informative\n           time-points for Step 2.\n\n        -  Step 2 will gather additional data on the cellular component of the vaccine-induced\n           immune response at selected time-points and will evaluate additional exploratory\n           read-outs of the innate immune response.\n\n      There will be 2 study groups in each step. The entire study period for Step 1 is from Day\n      -30  to Day 210 (240 days). The entire study period for Step 2 is from Day 0  to Day 210\n      (210 days)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who, in the opinion of the investigator, can and will comply with the\n             requirements of the protocol.\n\n          -  A male or female between, and including, 18 and 45 years of age at the time of first\n             study product administration.\n\n          -  Written informed consent obtained from the subject.\n\n          -  Healthy subjects, in the opinion of the investigator, as established by medical\n             history, clinical examination, and clinical laboratory assessment with no active\n             disease that could interfere with the study endpoints, before entering into the\n             study.\n\n          -  Body Mass Index (BMI) between 18.5 and 30 kg/m2.\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study\n\n               -  Non-childbearing potential is defined as pre-menarche, current tubal ligation,\n                  hysterectomy, ovariectomy or post-menopause.\n\n          -  Female subjects of childbearing potential may be enrolled in the study, if the\n             subject:\n\n               -  has practiced adequate contraception for 30 days prior to first study product\n                  administration and\n\n               -  has a negative pregnancy test on the day of placebo administration/ vaccination,\n                  and\n\n               -  has agreed to continue adequate contraception during the entire treatment period\n                  and for 2 months after completion of the study.\n\n        Exclusion Criteria:\n\n          -  Known history of HBV infection.\n\n          -  Previous vaccination against hepatitis B.\n\n          -  Positive for anti-hepatitis B surface (HBs) antibodies, anti-hepatitis B core (HBc)\n             antibodies, HBsAg, HCV antibodies and/or HIV.\n\n          -  Any previous administration of vaccine components.\n\n          -  Use of any investigational or non-registered product (drug or vaccine) other than the\n             study vaccines within 30 days preceding the first study product administration, or\n             planned use during the study period.\n\n          -  No significant dietary restrictions or life-threatening food allergies.\n\n          -  Regular use of non steroidal anti-inflammatory drugs within 1 month prior to first\n             study product administration.\n\n          -  Chronic administration (defined as more than 14 days in total) of immunosuppressants\n             or other immune-modifying drugs within 6 months prior to the first study product\n             administration. Inhaled and topical steroids are allowed.\n\n          -  Planned administration / administration of a vaccine not foreseen by the study\n             protocol in the period starting 30 days before the first study product administration\n             and during the entire study period (both Steps), with the exception of the influenza\n             vaccine (pandemic or seasonal) which can be administered > 21 days preceding or > 21\n             days following each placebo/vaccine administration.\n\n          -  Administration of immunoglobulins and/or any blood products within the last 3 months\n             preceding the first study product administration or planned administration during the\n             study period.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including\n             HIV based on screening evaluations and on medical history and physical examination.\n\n          -  History of or current bleeding or coagulation disorder.\n\n          -  Any known or clinical signs of anaemia or any clinical condition (including vascular\n             disorder) that would preclude frequent blood drawings.\n\n          -  Poor venous access as assessed at screening by the investigator.\n\n          -  Blood loss, including blood donation, of more than 300 mL within 90 days before the\n             first study product administration.\n\n          -  History of or current autoimmune or other immune-mediated disease.\n\n          -  Any haematological or biochemical level out of normal range before entering into the\n             study, as follows:\n\n               -  Haemoglobin level < lower normal limit (LNL).\n\n               -  Platelet counts out of normal range.\n\n               -  Alanine aminotransferase [ALT] > upper normal limit (UNL).\n\n               -  Aspartate aminotransferase [AST] > UNL.\n\n               -  Creatinine > UNL.\n\n               -  c-reactive protein [CRP] > UNL.\n\n               -  Creatine phosphokinase [CPK] > UNL without any plausible explanation for this\n                  abnormality (such as sport activity).\n\n        In case of haematological and/or biochemical value out of range for parameters mentioned\n        here above, one re-testing of out of range value may be performed.\n\n          -  Any acute or chronic, clinically significant disease, as determined by medical\n             history, physical examination or laboratory screening tests.\n\n          -  Known or suspected reaction or hypersensitivity likely to be exacerbated by any\n             component of the vaccines.\n\n          -  Acute disease and/or fever at the time of enrolment.\n\n               -  Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory\n                  infection) without fever may, be enrolled at the discretion of the investigator.\n\n               -  Fever is defined as temperature \u2265 37.5\u00b0C for oral route.\n\n          -  Pregnant or lactating female.\n\n          -  Recent history of chronic alcohol consumption and/or drug abuse.\n\n          -  Other conditions that the principal investigator judges may interfere with study\n             findings."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777295", 
            "org_study_id": "116640", 
            "secondary_id": "2012-001344-22"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group C", 
                    "Group A"
                ], 
                "description": "Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.", 
                "intervention_name": "Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group B", 
                    "Group D"
                ], 
                "description": "Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.", 
                "intervention_name": "EngerixTM-B", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Adults", 
            "Reactogenicity", 
            "Naive", 
            "Immune responses", 
            "Read-outs", 
            "Hepatitis B", 
            "Healthy"
        ], 
        "lastchanged_date": "March 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerpen", 
                    "country": "Belgium", 
                    "zip": "2060"
                }, 
                "name": "GSK Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "4", 
        "official_title": "Development of Read-outs to Detect and Characterise the Early and Adaptive Immune Responses in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen in Combination With a GSK Biologicals' Adjuvant System", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Innate/early immune response: Soluble mediators from the innate/early immune response in all subjects (Step 1 only).", 
            "safety_issue": "No", 
            "time_frame": "Day of study product administration (Day -30, Day 0 and Day 30) and during a 7-day follow-up period post study product administration."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777295"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adaptive response: Classical cellular and humoral immune response to components of the study vaccine in all subjects (Step 1 and 2).", 
                "safety_issue": "No", 
                "time_frame": "Day 0, Day 44, Day 60, Day 180 and Day 210."
            }, 
            {
                "measure": "Occurrence of solicited and non-serious unsolicited adverse events (AEs) (Step 1 and 2).", 
                "safety_issue": "No", 
                "time_frame": "Day of study product administration (Day -30 [step 1 only], Day 0 and Day 30 [both Steps]) and during a maximum of 28 day follow-up period post study product administration."
            }, 
            {
                "measure": "Occurrence of any serious adverse event (SAE) (Step 1 and 2).", 
                "safety_issue": "No", 
                "time_frame": "During the entire study period."
            }, 
            {
                "measure": "Occurrence of any Potential Immune-Mediated Disease (pIMD) (Step 1 and 2).", 
                "safety_issue": "No", 
                "time_frame": "During the entire study period."
            }, 
            {
                "measure": "Occurrence of any new medical condition requiring medical attention (Step 1 and 2).", 
                "safety_issue": "No", 
                "time_frame": "During the entire study period."
            }, 
            {
                "measure": "Safety laboratory parameters (Step 1 and 2).", 
                "safety_issue": "No", 
                "time_frame": "At Day 0, Day 1, Day 7, Day 30, Day 31, Day 37 and Day 60."
            }, 
            {
                "measure": "Vital signs at protocol defined time-points (Step 1 and 2).", 
                "safety_issue": "No", 
                "time_frame": "Day of study product administration (Day -30 [step 1 only], Day 0 and Day 30 [both Steps]) and during a 7 day follow-up period post study product administration."
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Public Private Partnership with Institute for Medical Immunology (Universite Libre de Bruxelles)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Region Wallonne", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}